A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer

NCT03371017 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

595

Enrollment

INDUSTRY

Sponsor class

Conditions

Triple Negative Breast Neoplasms

Interventions

DRUG: Atezolizumab
DRUG: Placebo
DRUG: Gemcitabine
DRUG: Capecitabine
DRUG: Carboplatin

Sponsor

Hoffmann-La Roche